RBF Capital’s Harvard Bioscience HBIO Stock Holding History

RBF Capital’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$98.4K	Hold	16,000	–	–	﹤0.01%	497
2026 Q1	$77.9K	Hold	16,000	–	–	﹤0.01%	482
2025 Q4	$107K	Hold	16,000	–	–	﹤0.01%	537
2025 Q3	$70.2K	Hold	16,000	–	–	﹤0.01%	568
2025 Q2	$71K	Sell	16,000 -2,091	-12%	-$8.74K	﹤0.01%	590
2025 Q1	$102K	Buy	+18,091	New	+$232K	0.01%	547
2015 Q2	–	Sell	-2,000	Closed	-$116K	–	332
2015 Q1	$116K	Hold	2,000	–	–	0.02%	277
2014 Q4	$113K	Hold	2,000	–	–	0.02%	272
2014 Q3	$82K	Sell	2,000 -213	-10%	-$9.8K	0.02%	273
2014 Q2	$101K	Sell	2,213 -1,176	-35%	-$49.4K	0.02%	266
2014 Q1	$161K	Hold	3,389	–	–	0.04%	254
2013 Q4	$159K	Sell	3,389 -1,081	-24%	-$47.2K	0.04%	259
2013 Q3	$178K	Hold	4,470	–	–	0.05%	246
2013 Q2	$159K	Buy	+4,470	New	+$171K	0.05%	244

Other funds holding HBIO

WCM

Weber Capital Management San Francisco, California $118M AUM

MIM

Meros Investment Management Dallas, Texas $315M AUM 58.44% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

CCM

Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RBF Capital's HBIO Position: Q2 2026 in Review

RBF Capital held its Harvard Bioscience (HBIO) position steady in Q2 2026 at 16,000 shares worth $98.4K. The position accounts for ﹤0.01% of the portfolio, ranked #497.

RBF Capital first reported a position in HBIO in Q2 2013 and has held it in 14 quarters since. The position peaked at $178K in Q3 2013. 37 funds tracked by Wall St. Rank hold HBIO as of Q2 2026.

RBF Capital held 16,000 shares of Harvard Bioscience worth $98.4K as of Q2 2026.
RBF Capital left its Harvard Bioscience share count unchanged in Q2 2026.
Harvard Bioscience made up ﹤0.01% of RBF Capital's portfolio in Q2 2026, its #497 holding.
RBF Capital first reported a position in Harvard Bioscience in Q2 2013 and has held it in 14 quarters since.
RBF Capital's Harvard Bioscience position peaked at $178K in Q3 2013.
37 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2026.

Based on RBF Capital's 13F filing for Q2 2026, filed 14 Aug 2026.